Neurocentrx Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Series A
  • (Upcoming)

  • Investors
  • 9

Neurocentrx General Information

Description

Developer of oral delivery medicines designed to treat patients with neurological conditions. The company's medicines are oral ketamine formulations that treat central nervous system conditions and cancer-related pain, enabling patients to alleviate severe and chronic neuropathic pain conditions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Level 5
  • 9 Haymarket Square
  • Edinburgh EH3 8RY
  • Scotland, United Kingdom
+44 0131
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • Level 5
  • 9 Haymarket Square
  • Edinburgh EH3 8RY
  • Scotland, United Kingdom
+44 0131

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurocentrx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series A) Upcoming Clinical Trials - Phase 2
8. Later Stage VC 23-Sep-2025 Completed Clinical Trials - Phase 2
7. Later Stage VC 12-May-2022 Completed Clinical Trials - Phase 2
6. Later Stage VC 28-Feb-2019 Completed Clinical Trials - Phase 2
5. Early Stage VC 23-May-2017 Completed Clinical Trials - Phase 1
4. Early Stage VC 29-Apr-2016 Completed Clinical Trials - Phase 1
3. Early Stage VC 31-Mar-2015 Completed Clinical Trials - Phase 1
2. Early Stage VC 25-Mar-2014 $482K $482K Completed Clinical Trials - Phase 1
1. University Spin-Out 18-Jul-2013 Completed Clinical Trials - Phase 1
To view Neurocentrx’s complete valuation and funding history, request access »

Neurocentrx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 465,418 $0.000010 $0.56 $0.56 1x $0.56 5.17%
Ordinary 1,481,933 $0.000010 $0.34 $0.34 1x $0.34 16.47%
To view Neurocentrx’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Neurocentrx Patents

Neurocentrx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202019952-D0 Novel compositions Inactive 17-Dec-2020
AU-2021404187-A1 Oral compositions comprising ketamine combined with subcutaneal or intravenous ketamine for use in the treatment, control or prevention of depressive disorders Pending 17-Dec-2020
AU-2021404187-A9 Oral compositions comprising ketamine combined with subcutaneal or intravenous ketamine for use in the treatment, control or prevention of depressive disorders Pending 17-Dec-2020
CA-3202522-A1 Oral compositions comprising ketamine combined with subcutaneal or intravenous ketamine for use in the treatment, control or prevention of depressive disorders Pending 17-Dec-2020
EP-4262769-A1 Oral compositions comprising ketamine combined with subcutaneal or intravenous ketamine for use in the treatment, control or prevention of depressive disorders Pending 17-Dec-2020 A61K31/135
To view Neurocentrx’s complete patent history, request access »

Neurocentrx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurocentrx Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
SPRIM Global Investments Holding Company Minority
Wellcome Trust Limited Partner Minority
Meltwind Advisory Venture Capital Minority
Neo Kuma Ventures Venture Capital Minority
O2h Ventures Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Neurocentrx FAQs

  • When was Neurocentrx founded?

    Neurocentrx was founded in 2013.

  • Where is Neurocentrx headquartered?

    Neurocentrx is headquartered in Edinburgh, United Kingdom.

  • What is the size of Neurocentrx?

    Neurocentrx has 6 total employees.

  • What industry is Neurocentrx in?

    Neurocentrx’s primary industry is Drug Discovery.

  • Is Neurocentrx a private or public company?

    Neurocentrx is a Private company.

  • What is Neurocentrx’s current revenue?

    The current revenue for Neurocentrx is .

  • How much funding has Neurocentrx raised over time?

    Neurocentrx has raised $6.15M.

  • Who are Neurocentrx’s investors?

    SPRIM Global Investments, Wellcome Trust, Meltwind Advisory, Neo Kuma Ventures, and O2h Ventures are 5 of 9 investors who have invested in Neurocentrx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process